S. Dewit et al., PHARMACOKINETICS OF 2 MULTIPLE-DOSING REGIMENS OF D0870 IN HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE PATIENTS - A PHASE-I STUDY, Antimicrobial agents and chemotherapy, 42(4), 1998, pp. 903-906
D0870 is a triazole,vith a broad antifungal spectrum, and it has been
shown to have both in vitro and in vivo activities against wild-type a
nd fluconazole-resistant strains of Candida albicans. Twenty-two human
immunodeficiency virus (HIV)-positive male subjects were enrolled in
an open, nonrandomized trial investigating the pharmacokinetics of two
different dosing regimens of D0870 and assessing the safety of multip
le oral doses of D0870 in HIV-positive subjects and their ability to t
olerate multiple oral doses. Nine subjects received an initial loading
dose of 50 mg, followed by four once-daily maintenance doses of 10 mg
. A further nine subjects received an initial 200-mg loading dose foll
owed by four daily maintenance doses of 25 mg. All subjects were fasti
ng. A single loading dose of 50 mg of D0870 resulted in a mean maximum
concentration in serum (C-max) of 107 +/- 32 ng/ml. Concentrations in
plasma were maintained by the 10-mg once-daily dosing regimen as seen
by the similar values of the area under the concentration-time curve
from 0 to 24 h following dosing on days 1 and 5 and a mean accumulatio
n ratio close to unity (0.90). The terminal plasma half-life of D0870
in plasma following dosing on day 5 ranged from 23 to 85 h (mean, 49 h
). A single loading dose of 200 mg of D0870 resulted in a C-max of 431
+/- 186 ng/ml. Concentrations in plasma were again maintained by the
25-mg daily dosing regimen, with the mean accumulation ratio being clo
se to unity (1.17). The terminal half-life of D0870 in plasma followin
g dosing on day 5 of phase II of the study ranged from 34 to 137 h (me
an, 71 h). In addition, the concentrations achieved in the plasma of t
hese HIV-positive subjects were similar to the values predicted from s
imulations based on data derived from normal, healthy subjects. D0870
was well tolerated. No serious adverse events were experienced during
the course of the study, and all volunteers completed the trial. A tot
al of 15 adverse events were reported, but none were considered to be
related to the administration of D0870 and all had resolved by the end
of the trial. No changes in the hematology, clinical chemistry, or ur
inalysis parameters were considered to be related to dosing with D0870
. No clinically significant changes in the electrocardiogram parameter
s were noted during the trial. The data generated in this trial suppor
t further investigation of these regimens with HIV-positive subjects w
ith fluconazole-susceptible or -resistant oropharyngeal candidosis.